Neuroblastoma: all 634 studies
Page 4 of 7. Open to participants first (122), then studies with results posted, then the rest; newest registration first within each.
- Nutritional Status in Neuroblastoma in Sao Paolo, BrazilCompletedNCT03517280
- Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)Active, not recruitingNCT03496402Not applicable
- Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruitingNCT03478462Phase 1
- SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain TumorsCompletedNCT03434262Phase 1
- Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed NeuroblastomaWithdrawnNCT03406273Not applicable
- Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid TumorsActive, not recruitingNCT03373097Phase 1/2
- Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone MarrowActive, not recruitingNCT03363373Phase 2
- Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK CellsStatus unknownNCT03242603Phase 1/2
- A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory MalignanciesCompletedNCT03236857Phase 1
- Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2WithdrawnNCT03209869Phase 1
- Study of Chemoimmunotherapy for High-Risk NeuroblastomaActive, not recruitingNCT03189706Early Phase 1
- Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk NeuroblastomaStatus unknownNCT03061656Phase 2
- Late Effects After Treatment in Patients With Previously Diagnosed High-Risk NeuroblastomaActive, not recruitingNCT03057626
- Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma PatientsCompletedNCT03042429Phase 3
- 18F-DOPA PET Imaging: an Evaluation of Biodistribution and SafetyCompletedNCT03042416Phase 3
- A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk NeuroblastomaCompletedNCT03033303Phase 2
- Dosimetry Guided PRRT With 90Y-DOTATOCWithdrawnNCT03013387Phase 2
- Racotumomab in Patients With High-risk NeuroblastomaCompletedNCT02998983Phase 2
- Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid TumorsCompletedNCT02982941Phase 1
- G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Phase 4
- Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in ChildrenStatus unknownNCT02919046Not applicable
- Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory NeuroblastomaActive, not recruitingNCT02914405Phase 1
- Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaCompletedNCT02909777Phase 1
- Neuroblastoma Precision TrialActive, not recruitingNCT02868268
- Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic ClassificationCompletedNCT02864563Not applicable
- Next Generation Personalized Neuroblastoma TherapyTerminatedNCT02780128Phase 1
- Response-based Treatment of High-risk NeuroblastomaStatus unknownNCT02771743Phase 2
- Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent NeuroblastomaCompletedNCT02765243Phase 1
- A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory MedulloblastomaCompletedNCT02748135Phase 1
- A Combined Cell Therapy Approach to the Treatment of NeuroblastomaWithdrawnNCT02745756Phase 1
- Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed NeuroblastomaStatus unknownNCT02743429Phase 2
- Neuroblastoma Maintenance Therapy TrialActive, not recruitingNCT02679144Phase 2
- Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaCompletedNCT02650648Phase 1
- Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsActive, not recruitingNCT02650401Phase 1/2
- Abemaciclib in Children With DIPG or Recurrent/Refractory Solid TumorsCompletedNCT02644460Phase 1
- NB2013-HR German (GPOH) / Dutch (DCOG) TrialTerminatedNCT02641782Phase 2
- Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk NeuroblastomaCompletedNCT02641314Phase 2
- Trial of Tolcapone With Oxaliplatin for NeuroblastomaTerminatedNCT02630043Phase 1
- Anti-angiogenetic Therapy With Radiotherapy for Pediatric NeuroblastomaStatus unknownNCT02615106Phase 2
- Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS TumorsActive, not recruitingNCT02574728Phase 2
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsActive, not recruitingNCT02573896Phase 1
- HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid TumorsWithdrawnNCT02557854Phase 1
- A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid TumorsTerminatedNCT02536183Phase 1
- T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing MalignanciesStatus unknownNCT02457650Phase 1
- MLN8237 to Treat Children With Relapsed/Refractory Solid TumorsCompletedNCT02444884Phase 1
- 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMAWithdrawnNCT02439788Phase 1
- 18F-FDOPA PET in Neuroendocrine TumoursNo longer availableNCT02431715
- Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS TumorsCompletedNCT02390843Phase 1
- SF1126 for Patients With Relapsed or Refractory NeuroblastomaTerminatedNCT02337309Phase 1
- Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01Active, not recruitingNCT02311621Phase 1
- Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in ChildrenCompletedNCT02308527Phase 2
- PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot StudyActive, not recruitingNCT02307630Not applicable
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaActive, not recruitingNCT02298348Phase 1
- Parental Decision-Making for Children With Relapsed NeuroblastomaActive, not recruitingNCT02282735
- CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed NeuroblastomaCompletedNCT02258815Phase 2
- Local Control With Reduced-dose Radiotherapy for High-Risk NeuroblastomaCompletedNCT02245997Early Phase 1
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk NeuroblastomaActive, not recruitingNCT02176967Phase 3
- Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and OsteosarcomaStatus unknownNCT02173093Phase 1/2
- Safety Study of Dinutuximab Combined With Immunotherapy to Treat NeuroblastomaCompletedNCT02169609Phase 2
- ODSH + ICE Chemotherapy in Pediatric Solid TumorsTerminatedNCT02164097Phase 1
- Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant NeuroblastomaTerminatedNCT02163356Phase 1
- Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A AntibodyCompletedNCT02159443
- A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or LymphomasCompletedNCT02130869Phase 1
- Phase II Study of Proton Radiation Therapy for NeuroblastomaActive, not recruitingNCT02112617Not applicable
- A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid TumorsCompletedNCT02107963Phase 1
- MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid TumorsCompletedNCT02076906Phase 1
- Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in NeuroblastomaNo longer availableNCT02075177
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/TopotecanCompletedNCT02030964Phase 1
- Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid TumorsWithdrawnNCT02011126Phase 2
- A Pilot Study on ALK Gene Mutations in NeuroblastomaStatus unknownNCT01986595
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and NeuroblastomaActive, not recruitingNCT01953900Phase 1
- Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With NeuroblastomaStatus unknownNCT01943097
- Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With NeuroblastomaWithdrawnNCT01916187Phase 1
- NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid TumorsCompletedNCT01875601Phase 1
- Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)CompletedNCT01868269Phase 3
- iCAT for Recurrent/Refractory/HR Solid TumorsCompletedNCT01853345
- MIBG for Refractory Neuroblastoma and PheochromocytomaCompletedNCT01850888Not applicable
- Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or ParagangliomaNo longer availableNCT01838187
- 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAINActive, not recruitingNCT01822652Phase 1
- Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid TumorsStatus unknownNCT01807468Phase 2
- A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed NeuroblastomaCompletedNCT01802138Not applicable
- Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk NeuroblastomaActive, not recruitingNCT01757626Phase 1/2
- European Low and Intermediate Risk Neuroblastoma ProtocolCompletedNCT01728155Phase 3
- Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALLCompletedNCT01713439Phase 1
- Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent NeuroblastomaActive, not recruitingNCT01711554Phase 1
- ch14.18/CHO Bridging StudyCompletedNCT01704872Phase 1
- Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)Status unknownNCT01701479Phase 1/2
- Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid TumorsCompletedNCT01662804Phase 1
- Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of NeuroblastomaCompletedNCT01638572
- A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and LymphomasCompletedNCT01625351Phase 1
- Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated GangliosidesCompletedNCT01598454Phase 1
- Studying Chromosomes in Samples From Younger Patients With NeuroblastomaCompletedNCT01589341
- 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot StudyTerminatedNCT01583842Early Phase 1
- Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory NeuroblastomaCompletedNCT01576692Phase 1
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Studying Gene Expression in Samples From Younger Patients With NeuroblastomaCompletedNCT01553448
- High Dose Chemotherapy and Autologous Transplant for NeuroblastomaCompletedNCT01526603Not applicable
- Nurse Case Manager Model on Neuroblastoma Caregiver's UncertaintyStatus unknownNCT01525251
- Gene Expression in Predicting Outcome in Samples From Patients With High-Risk NeuroblastomaCompletedNCT01520233
- Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid TumorsCompletedNCT01518413Phase 1